Durability and long-term outcomes of biologic therapies in psoriasis.

Abstract

INTRODUCTION:

Significant advances in psoriasis treatment have taken place since the introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics approved and at that time greatly improved psoriasis treatment. However, newer biologics, directed to interleukin(IL)-23/IL-17 pathways central to psoriasis pathogenesis, have improved complete or nearly complete clearance rates and are characterized by an excellent safety profile.Real-world setting experiences have generally confirmed the results of clinical trials, but real-world data regarding newer biologics is relatively scarce.

AREAS COVERED:

We provide an extensive review of real-world survival of biologic treatments for moderate to severe psoriasis.

EXPERT OPINION:

There is growing and consistent evidence of higher drug survival of IL-23 inhibitors, possibly due to their favorable efficacy and safety profiles, dosing convenience and persistence of response despite treatment interruption; eventual confirmation of their potential role as modifiers of the natural history of psoriasis might provide additional reasons for therapeutic persistence of this class of biologics.

• Authors: Lluís Rusiñol, Elena Carmona-Rocha, Lluís Puig
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Pg. 1-12 (Aug 25 2023) ISSN: 1744-8409 [Electronic] England
• PMID: 37610817 (Publication Type: Journal Article, Review)